PharmaGABA (Natural GABA).

GABA is made by decarboxylating glutamate, and that enzyme runs on pyridoxal phosphate. B6 supports the body's own production of the same molecule the supplement supplies.

Glutamine crosses into neurons and is converted to glutamate, the direct substrate for GABA synthesis. It sits two steps upstream of the finished transmitter.

Theanine raises alpha wave activity and modulates glutamate signalling while GABA acts on inhibitory receptors. The two mechanisms are distinct, which is why they are formulated together.

Magnesium sits in the NMDA receptor pore, damping the excitatory arm, and positively modulates GABA-A. It works on both sides of the same excitation and inhibition balance.

Glycine acts at its own chloride channel in the brainstem and cord while GABA acts at GABA-A. Both open chloride channels through separate receptors.

Taurine is a weak agonist at both glycine and GABA-A receptors and also influences chloride handling. It reinforces the same inhibitory tone from an overlapping receptor set.

Apigenin binds the benzodiazepine site of the GABA-A receptor, which raises the response to whatever GABA is present. It modulates the receptor rather than adding transmitter.

Valerian constituents interact with GABA-A subunits and slow GABA breakdown. It acts on the receptor and the turnover of the same transmitter.

Rosmarinic acid in lemon balm inhibits GABA transaminase, the enzyme that clears GABA. Slowing clearance extends the action of the transmitter.

Honokiol and magnolol positively modulate GABA-A receptors at a site separate from the benzodiazepine one. The effect adds to the transmitter itself.

Chamomile's calming activity is largely attributed to its apigenin, a benzodiazepine site ligand. It is a plant source of the same receptor modulation.

Passionflower flavonoids interact with GABA-A binding sites and influence GABA uptake. The activity runs through the same receptor system.

Melatonin acts on circadian timing receptors rather than chloride channels. Sleep formulas pair them because the timing signal and the inhibitory signal are separate levers.

Caffeine blocks adenosine receptors and raises arousal, the opposite of the inhibitory tone GABA supports. Placing both in one formula pulls central signalling in two directions.

Glutamate decarboxylase converts glutamate to GABA and cannot work without pyridoxal-5-phosphate bound in its active site. P5P is the already-phosphorylated form, so it does not depend on the pyridoxal kinase step that pyridoxine requires. The cofactor relationship is textbook and needs no combination trial.

Magnesium sits in the NMDA receptor channel as a voltage-dependent block on excitatory signalling, and the glycinate carrier delivers glycine, which acts on its own inhibitory receptor in the brainstem and spinal cord. Both push the excitation and inhibition balance in the same direction as GABA. The receptor pharmacology is established; the combined subjective effect is not something a trial in the available set measures.

Tryptophan is hydroxylated to 5-hydroxytryptophan and decarboxylated to serotonin, a step that shares the same pyridoxal-5-phosphate dependent decarboxylase chemistry as GABA formation. Evening formulas often carry both because they act through different receptor systems. Precursor supply is established biochemistry; whether it changes sleep measures depends on competition with other large neutral amino acids at the blood brain barrier.

5-hydroxytryptophan skips tryptophan hydroxylase, the rate-limiting enzyme, and is decarboxylated directly to serotonin by aromatic L-amino acid decarboxylase, another pyridoxal-5-phosphate enzyme. It is commonly stacked with GABA in evening formulas. Because it acts on the serotonin system, it warrants caution with any serotonergic medication, and that caution is established pharmacology.

Myo-inositol is the backbone of phosphatidylinositol and the source of the inositol trisphosphate second messenger used by many G protein coupled receptors, including several serotonergic and adrenergic ones. It appears alongside GABA in calm-support formulas on that basis. The signalling role is established; the behavioural claim built on it is much weaker.

Withanolide fractions from Withania somnifera have shown GABA-mimetic activity at the GABA-A receptor in laboratory preparations, which is the mechanistic reason the two are formulated together. That is in vitro pharmacology, not a demonstrated additive effect in people. Any additive calming effect should be read as expected rather than measured.

Rhodiola's salidroside and rosavin fraction is associated with monoamine and stress-axis effects rather than direct GABA receptor activity, so it is often positioned as the daytime counterpart in a formula. Pairing it with GABA is a category decision rather than a mechanistic one. Rhodiola can be activating in some people, which makes the direction of the combined effect uncertain.

Zinc inhibits GABA-A receptor currents at certain subunit combinations in electrophysiological work, so it does not simply add to GABAergic tone. This is a direction worth flagging rather than a warning: the effect is subunit-dependent and measured in laboratory preparations, not in people taking a supplement. It is included because an anti-synergy is as useful to a formulator as a positive one.

Hop constituents have shown GABA-A receptor activity in laboratory preparations and hops has been paired with valerian in European sleep preparations for a long time. The additive sedation direction is what a formulator should expect. Combined use with anything else sedating, including alcohol, warrants the same caution.

Standardised oral lavender oil preparations have their own literature in calm support and are proposed to act on voltage-gated calcium channels rather than on GABA receptors directly. That makes the pairing complementary in mechanism. The additive direction is sedation, so it belongs in the same caution group as the other calming botanicals.

Reishi appears in evening and calm formulas through long traditional use rather than through a documented receptor mechanism shared with GABA. Its triterpene and polysaccharide fractions are unrelated chemically. The pairing is formulation convention.

Free-form GABA is supplied as a zwitterionic amino acid, but some manufacturing and food-grade routes deliver it in salt form, which changes the sodium contributed per gram. In a beverage or powdered drink at gram-level doses that difference is worth reading off the label. This is formulation arithmetic rather than pharmacology.

Nicotinamide has been reported to bind weakly at the benzodiazepine site of the GABA-A receptor in laboratory binding studies, which is the origin of its occasional appearance in calm formulas. The affinity reported is low and the finding has not been carried into human work. It is included at low confidence and flagged as in vitro only.